Patent · US Active

Antibodies specific for CD70 and their uses

US11377500B2 · kind B2 · utility

0Cited by
64References
36Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 31, 2019
Grant dateJul 5, 2022
Priority date
Expiry dateNov 30, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.